Harry H. Penner, Jr.

Chairman of the Board of Directors

Mr. Penner, a serial entrepreneur, is a Founder of Affinimark Technologies, Inc., Marinus Pharmaceuticals, Inc. (MRNS: Nasdaq), Rib-X Pharmaceuticals (now Melinta Therapeutics, Inc.), Omax Health, Inc., RxGen, Inc., MAK Scientific, LLC, New Haven Pharmaceuticals, Inc., NeuroCyte Therapeutics, Inc., and QCDx, Inc. Mr. Penner was President, Chief Executive Officer, and Vice Chairman of Neurogen Corporation (a publicly traded bioscience company) from 1993 to 2001. From 1985 to 1993 Penner was an Executive Vice President of Novo Nordisk A/S (NVO: NYSE), serving from 1985 to 1988 as the company’s Executive Vice President and General Counsel in Denmark, and serving from 1988 to 1993 as Executive Vice President for North America and President of Novo Nordisk North America.

He has served as BioScience Advisor to the Governor and the State of Connecticut, as Chair of the Connecticut Board of Governors of Higher Education, Chair of the Connecticut Technology Council, and as Co-Chair of CURE (now BioCT). Mr. Penner currently serves on the board of directors for Celldex Therapeutics (CLDX: Nasdaq) and chairs the board of Affin-imark Technologies. He also serves as a member of SECT Tech, an economic development endeavor sponsored by Connecticut Innovations.

Mr. Penner holds a B.A. from the University of Virginia, a J.D. from Fordham University, an L.L.M. in International Law from New York University, and certificates from Stanford University’s GSB executive management programs.